- Conditions
- Schizophrenia
- Interventions
- Pimavanserin, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Rogers, Arkansas • Bellflower, California + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 57
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- MMFS-202-302, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Schizophrenia
- Interventions
- rasagiline (Pharmacodynamics), Placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
- Conditions
- Schizophrenia
- Interventions
- Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Schizophrenia
- Interventions
- 1 Hz rTMS, 10 Hz rTMS
- Device
- Lead sponsor
- Seton Healthcare Family
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Pravastatin
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Schizophrenia
- Interventions
- PF-03463275, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 37
- States / cities
- Cerritos, California • Chula Vista, California • Escondido, California + 26 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, RO5545965
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Glendale, California • St Louis, Missouri
- Conditions
- Schizophrenia
- Interventions
- Oxytocin, Galantamine, Placebo-Oxytocin, Placebo-Galantamine
- Drug · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
- Conditions
- Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
- Interventions
- N-acetylcysteine, Treatment as Usual
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Schizophrenia
- Interventions
- Modafinil, Placebo
- Drug
- Lead sponsor
- Veterans Medical Research Foundation
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Schizophrenia
- Interventions
- Digital therapeutic (CT-155)
- Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 31
- States / cities
- Imperial, California • La Jolla, California • Oceanside, California + 25 more
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders
- Interventions
- risperidone, sertraline-primary
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 12 Years to 22 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia
- Interventions
- Oral Glucose Tolerance Test (OGTT)
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia
- Conditions
- Schizophrenia
- Interventions
- modafinil, Placebo
- Drug
- Lead sponsor
- North Suffolk Mental Health Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- RO6889450, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 28
- States / cities
- Bellflower, California • Garden Grove, California • Glendale, California + 23 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- d-cycloserine, glycine, placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Glen Oaks, New York + 1 more
- Conditions
- Negative Symptoms of Schizophrenia
- Interventions
- Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg
- Drug
- Lead sponsor
- Minerva Neurosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Rogers, Arkansas • Culver City, California • Garden Grove, California + 10 more
- Conditions
- Schizoaffective Disorder, Schizophrenia
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 4,914 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Schizophrenia
- Interventions
- Luvadaxistat, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 16
- States / cities
- Garden Grove, California • Lemon Grove, California • Los Angeles, California + 13 more
- Conditions
- Schizophrenia
- Interventions
- CBSST-CCT, Goal focused supportive contact
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Schizophrenia
- Interventions
- CT-155, Digital Control
- Device
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 54
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 50 more
- Conditions
- Schizophrenia
- Interventions
- SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- Schizophrenia
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 17
- States / cities
- Cerritos, California • Garden Grove, California • National City, California + 14 more